ASX 200 ends up 1pc; Guzman IPO
Guzman y Gomez to list with $2.2bn value. Telix jumps on cancer drug ‘signal’. Household savings hit fresh record. Rival offer may revive BHP’s Anglo bid: Morningstar. CSL to help US stockpile avian flu vax.
Csl
What to do when your business flight is cancelled
Hit with two flight cancellations on work trips recently I realised delays are unavoidable these days. Here’s what you can do about it.
Quest to unearth next CSL begins in Victoria
Sixteen early stage ventures have taken residence in CSL’s Melbourne headquarters as part of a new biotech incubator that aims to build Australia’s next health juggernaut.
Why this top fund manager is backing gold
Collins St Asset Management says a valuation gap with gold miners is set to close rapidly, potentially within months. Also today: EY prepares to announce layoffs. RBNZ holds rates. Dubber sacks CEO.
International group scoops historic manufacturing site
Animal health company Zoetis has secured a historic manufacturing site in Melbourne’s most prominent biomedical research precinct from the Victorian government.
ASX 200 ends at record high
ASX 200 sets all-time high at close. Life360 soars 38 per cent on earnings beat. ASIC wants crime-linked Prospero wound up. China manufacturing activity better than expected but still weak.
Equal pay should lift productivity
It is in companies’ interests to pay staff fairly, regardless of gender.
CSL posts ‘strong’ result as plasma division delivers
An ‘exceptional’ performance from its plasma division has underpinned an uplift in first half profit with CSL reaffirming its full year growth outlook.
AGL’s Loy Yang hit by outage; ASX closes weaker
ASX 200 closes down 0.2pc at 7603.6points. Loy Yang A station offline. Callide C station failure report out. Macquarie hit by profit warning, star exit. Challenger lifts. Seek, Lew-backed Breville, Seven West and James Hardie fall.
ASX down as major drug trial scrapped
The Australian sharemarket fell on Monday after biotech giant CSL dropped its plans to continue with a major drug trial.
Heartbreak as CSL trial disappoints
The news was all bad for CSL when top-line results lobbed from its Phase 3 trial of a treatment to reduce the consequences of heart attacks.
CSL will still bet on blockbuster drugs
There were high hopes for a wonder drug being developed by CSL which failed. The pharma giant is still taking the win from the loss.
‘Herculean’ CSL drug trial falls flat
The biggest drug trial in CSL’s history, which sought to find a treatment for recurrent cardiac events, has failed to deliver the desired result.
CSL drags ASX lower; JB Hi-Fi gains
CSL weighs down market after disappointing cardiac drug trial. Fletcher halts for earnings guidance, CEO future update. Synlait sinks on earnings warning. Retailer JB Hi-Fi up as profit beats estimates.
Carbon capture needs to be more than just aspiration
To combat climate change we must use technology available to us now, such as removing CO2 from processing or industrial facilities, and burying it underground.
Quit RBA board, CSL directors told
Unions want CSL directors Carolyn Hewson and Alison Watkins to quit the RBA board due to CSL’s ‘corporate bastardry’.
Funds must put members first
Two powerful trade unions urging eight superannuation funds to review investment in Australia’s third-largest company, CSL, should stick to their day jobs.
Dump CSL, super funds told
Unions declare workers’ funds should not be used to finance CSL’s corporate bastardry.
Union plan to put boss in dock
CSL chief executive Paul McKenzie faces legal action after exposure of the company’s plan to cut workers’ pay.
ASX gains but post-CPI rally fades
RBA tipped to hold rates next week after inflation cools more than expected. Strong Harvey Norman protest vote as sales slow. Fisher & Paykel, CSL, Temple & Webster among gainers.
Original URL: https://www.theaustralian.com.au/topics/csl/page/2